Specificity of immunoassays

Pratt, John J.; Woldring, Mg; Boonman, Ria; Bosman, W.

doi:10.1007/bf00620481

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The amount of testosterone antiserum to be added to the assay System was estirn ted experimentally according toPratt (8), s the antiserum dilution at which the crossreaction of the chosen amount of the competitpr (0.345 prnol i.e. 100 pg, corresppnding to mid-values in analyzed samples) is less th n 0.1.…”

Section: Characterization Of the Antiseramentioning

confidence: 99%

A Selective Radioimmunoassay of Androstenedione in Plasma and Saliva

Putz¹,

Hampl²,

Vaňuga³

et al. 1982

CCLM

View full text Add to dashboard Cite

A specific radioimmunoassay for 4-androstene-3,17-dione (androstenedione) based on rabbit antisera to 6j3-hydrpxy-4-androstene-3,17-dione^6-hemisuccinate-bovine serum albumin conjugate was developed. Cross reaction by testosteröne was eliminated by additipn of experimentally established amounts of testosterone antiserum, which cross reacted by only 0.004 with androstenedione. The method has been used fpr simultaneous determination of androstenedione in both plasma and saliva of normal women under basal conditions and following dynamic tests. The plasma levels in normal women averaged 3.6 ± 0.9 nmol/1 and cprrelated (r -0.93) with those found in saliva (0.353 ± 0.089 nmol/1).

show abstract

Section: Characterization Of the Antiseramentioning

confidence: 99%

A Selective Radioimmunoassay of Androstenedione in Plasma and Saliva

Putz¹,

Hampl²,

Vaňuga³

et al. 1982

CCLM

View full text Add to dashboard Cite

show abstract

Ligand‐Binding Assays

Verch

Bakhtiar

2012

Encyclopedia of Drug Metabolism and Interactions

View full text Add to dashboard Cite

Ligand‐binding assays (LBAs) or immunoassays are the analytical method of choice for pharmacokinetic (PK) and immunogenicity assessment for biopharmaceuticals. As pipelines for this class of drugs are expanding, immunoassays are revisited to address current scientific questions with this classic technology. Although formats and technologies are ever expanding, the basic principle remains the same: analytes of interest are captured and/or detected in unpurified samples using specific antibodies. The technology of choice often depends on the balance between sensitivity, life cycle, and cost. Regardless of assay technologies, close attention should be paid to reagent quality and potential matrix effects. PK measurements in particular rely on LBAs to detect biologic drugs in unpurified patient sera. A combination of white papers and evolving regulatory guidelines governs the use and validation of LBAs to measure both therapeutic drugs for PK and anti‐drug antibodies for immunogenicity during preclinical and clinical development.

show abstract

Interferences in Immunoassays

Miller

Levinson²

1996

Immunoassay

View full text Add to dashboard Cite

Specificity of immunoassays

Cited by 4 publications

References 12 publications

A Selective Radioimmunoassay of Androstenedione in Plasma and Saliva

A Selective Radioimmunoassay of Androstenedione in Plasma and Saliva

Ligand‐Binding Assays

Interferences in Immunoassays

Contact Info

Product

Resources

About